Symbols / IGC
IGC Chart
About
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 26.51M |
| Enterprise Value | 24.92M | Income | -6.45M | Sales | 1.11M |
| Book/sh | 0.09 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 70 | IPO | — |
| P/E | — | Forward P/E | -3.10 | PEG | — |
| P/S | 23.97 | P/B | 3.17 | P/C | — |
| EV/EBITDA | -3.31 | EV/Sales | 22.53 | Quick Ratio | 0.79 |
| Current Ratio | 1.32 | Debt/Eq | 1.80 | LT Debt/Eq | — |
| EPS (ttm) | -0.07 | EPS next Y | -0.09 | EPS Growth | — |
| Revenue Growth | -53.60% | Earnings | 2025-11-14 16:00 | ROA | -50.31% |
| ROE | -83.34% | ROIC | — | Gross Margin | 46.20% |
| Oper. Margin | -15.18% | Profit Margin | 0.00% | Shs Outstand | 95.04M |
| Shs Float | 84.64M | Short Float | 0.82% | Short Ratio | 1.33 |
| Short Interest | — | 52W High | 0.50 | 52W Low | 0.24 |
| Beta | 0.32 | Avg Volume | 587.15K | Volume | 567.00K |
| Target Price | $4.00 | Recom | Strong_buy | Prev Close | $0.27 |
| Price | $0.28 | Change | 4.85% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.00
Mean price target
2. Current target
$0.28
Latest analyst target
3. DCF / Fair value
$-0.48
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.28
Low
$3.00
High
$5.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-12-09 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-08-26 | main | Ascendiant Capital | Buy → Buy | $5 |
| 2025-03-06 | reit | Alliance Global Partners | Buy → Buy | $4 |
| 2025-02-24 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-12-05 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-09-03 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-07-29 | main | Ascendiant Capital | Buy → Buy | $4 |
| 2024-07-17 | init | Alliance Global Partners | — → Buy | $4 |
| 2024-06-21 | reit | Ascendiant Capital | Buy → Buy | $3 |
News
RSS: Latest IGC news- Analyst lifts IGC Pharma price target to $5 in new research note - Stock Titan ue, 24 Feb 2026 13
- IGC Stock: Ascendiant Capital Maintains Buy Rating, Raises Price - GuruFocus Mon, 23 Feb 2026 10
- New Analyst Forecast: $IGC Given $5 Price Target - Quiver Quantitative Mon, 23 Feb 2026 10
- IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets (2026-02-24) - Seeking Alpha ue, 24 Feb 2026 13
- Miami neurology network joins Alzheimer’s agitation drug trial - Stock Titan Mon, 23 Feb 2026 13
- Would You Still Hold IGC Pharma Stock If It Fell Another 30%? - Trefis Sat, 20 Dec 2025 08
- IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance Fri, 14 Nov 2025 08
- All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy - Nasdaq Fri, 24 Oct 2025 07
- Aug Final Week: Is IGC Pharma Inc a cyclical or defensive stock - Watch List & Real-Time Sentiment Analysis - baoquankhu1.vn ue, 24 Feb 2026 17
- Alzheimer’s agitation trial passes 70% enrollment milestone - Stock Titan Mon, 02 Feb 2026 08
- IGC Pharma (IGC): Ascendiant Capital Raises Price Target to $4.7 - GuruFocus ue, 09 Dec 2025 08
- IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance hu, 14 Aug 2025 07
- Low-dose THC Alzheimer’s drug from IGC wins key North America patent - Stock Titan ue, 17 Feb 2026 13
- IGC Pharma (IGC) spotlights Alzheimer's cannabinoid trial amid Schedule III talks - Stock Titan Mon, 15 Dec 2025 08
- IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers - Yahoo Finance Mon, 17 Nov 2025 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | — | — | MUKUNDA RAM | Chief Executive Officer | — | 2026-02-03 00:00:00 | I | nan |
| 1 | 100000 | — | — | PRINS RICHARD K | Director | — | 2026-01-16 00:00:00 | D | nan |
| 2 | 100000 | — | Stock Gift at price 0.00 per share. | MUKUNDA RAM | Chief Executive Officer | — | 2025-10-17 00:00:00 | D | — |
| 3 | 50000 | — | Stock Gift at price 0.00 per share. | GRIMALDI CLAUDIA | Officer and Director | — | 2025-10-17 00:00:00 | D | — |
| 4 | 566666 | — | — | MUKUNDA RAM | Chief Executive Officer | — | 2025-03-31 00:00:00 | D | nan |
| 5 | 228333 | — | — | PRINS RICHARD K | Director | — | 2025-03-31 00:00:00 | D | nan |
| 6 | 158333 | — | — | GRIMALDI CLAUDIA | Director | — | 2025-03-31 00:00:00 | D | nan |
| 7 | 163333 | — | — | MORAN JAMES P | Director | — | 2025-03-31 00:00:00 | D | nan |
| 8 | 588235 | — | Purchase at price 0.34 per share. | MORAN JAMES P | Director | — | 2024-09-25 00:00:00 | I | 200000.0 |
| 9 | 200000 | — | Stock Gift at price 0.00 per share. | PRINS RICHARD K | Director | — | 2024-08-12 00:00:00 | D | — |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.83M | -5.82M | -10.91M | -14.73M |
| TotalUnusualItems | 0.00 | -3.35M | 0.00 | -49.00K |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -3.35M | 0.00 | -49.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.12M | -13.00M | -11.51M | -15.02M |
| ReconciledDepreciation | 618.00K | 637.00K | 657.00K | 651.00K |
| ReconciledCostOfRevenue | 652.00K | 612.00K | 469.00K | 203.00K |
| EBITDA | -6.83M | -9.16M | -10.91M | -14.78M |
| EBIT | -7.45M | -9.80M | -11.57M | -15.43M |
| NormalizedIncome | -7.12M | -9.65M | -11.51M | -14.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.12M | -13.00M | -11.51M | -15.02M |
| TotalExpenses | 8.72M | 11.14M | 12.48M | 15.82M |
| TotalOperatingIncomeAsReported | -7.45M | -9.80M | -11.57M | -15.43M |
| DilutedAverageShares | 76.52M | 58.84M | 52.58M | 49.99M |
| BasicAverageShares | 76.52M | 58.84M | 52.58M | 49.99M |
| DilutedEPS | -0.09 | -0.22 | -0.22 | -0.30 |
| BasicEPS | -0.09 | -0.22 | -0.22 | -0.30 |
| DilutedNIAvailtoComStockholders | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncomeCommonStockholders | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncome | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncomeIncludingNoncontrollingInterests | -7.12M | -13.00M | -11.51M | -15.02M |
| NetIncomeContinuousOperations | -7.12M | -13.00M | -11.51M | -15.02M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -7.12M | -13.00M | -11.51M | -15.02M |
| OtherIncomeExpense | 325.00K | -3.20M | 65.00K | 412.00K |
| OtherNonOperatingIncomeExpenses | 325.00K | 143.00K | 65.00K | 461.00K |
| SpecialIncomeCharges | 0.00 | -3.35M | 0.00 | -49.00K |
| WriteOff | 0.00 | 49.00K | 169.00K | |
| ImpairmentOfCapitalAssets | 0.00 | 3.35M | 0.00 | |
| OperatingIncome | -7.45M | -9.80M | -11.57M | -15.43M |
| OperatingExpense | 8.06M | 10.53M | 12.01M | 15.62M |
| ResearchAndDevelopment | 3.65M | 3.77M | 3.46M | 2.33M |
| SellingGeneralAndAdministration | 4.41M | 6.76M | 8.55M | 13.29M |
| GrossProfit | 619.00K | 733.00K | 442.00K | 194.00K |
| CostOfRevenue | 652.00K | 612.00K | 469.00K | 203.00K |
| TotalRevenue | 1.27M | 1.34M | 911.00K | 397.00K |
| OperatingRevenue | 1.27M | 1.18M | 911.00K | 397.00K |
| Line Item | 2024-03-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 80.88M | 66.69M | 53.08M | 51.05M |
| ShareIssued | 80.88M | 66.69M | 53.08M | 51.05M |
| TotalDebt | 238.00K | 345.00K | 481.00K | 608.00K |
| TangibleBookValue | 4.48M | 5.71M | 13.74M | 22.98M |
| InvestedCapital | 6.46M | 7.46M | 15.05M | 24.04M |
| WorkingCapital | 639.00K | 1.36M | 4.57M | 12.67M |
| NetTangibleAssets | 4.48M | 5.71M | 13.74M | 22.98M |
| CapitalLeaseObligations | 104.00K | 208.00K | 340.00K | 464.00K |
| CommonStockEquity | 6.33M | 7.32M | 14.91M | 23.89M |
| TotalCapitalization | 6.46M | 7.46M | 15.05M | 24.04M |
| TotalEquityGrossMinorityInterest | 6.33M | 7.32M | 14.91M | 23.89M |
| StockholdersEquity | 6.33M | 7.32M | 14.91M | 23.89M |
| GainsLossesNotAffectingRetainedEarnings | -3.50M | -3.42M | -3.39M | -2.97M |
| OtherEquityAdjustments | -3.50M | -3.42M | -3.39M | -2.97M |
| RetainedEarnings | -120.74M | -113.67M | -100.67M | -89.16M |
| CapitalStock | 130.57M | 124.41M | 118.97M | 116.02M |
| CommonStock | 130.57M | 124.41M | 118.97M | 116.02M |
| PreferredStock | 0.00 | |||
| TotalLiabilitiesNetMinorityInterest | 2.42M | 2.58M | 2.27M | 2.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 160.00K | 241.00K | 369.00K | 501.00K |
| LongTermDebtAndCapitalLeaseObligation | 144.00K | 221.00K | 348.00K | 485.00K |
| LongTermCapitalLeaseObligation | 10.00K | 84.00K | 207.00K | 341.00K |
| LongTermDebt | 134.00K | 137.00K | 141.00K | 144.00K |
| LongTermProvisions | 16.00K | 20.00K | 21.00K | 16.00K |
| CurrentLiabilities | 2.26M | 2.34M | 1.90M | 2.44M |
| OtherCurrentLiabilities | 1.00M | 419.00K | 358.00K | 180.00K |
| CurrentDebtAndCapitalLeaseObligation | 94.00K | 124.00K | 133.00K | 123.00K |
| CurrentCapitalLeaseObligation | 94.00K | 124.00K | 133.00K | 123.00K |
| CurrentDebt | 3.00K | 304.00K | ||
| OtherCurrentBorrowings | 3.00K | 304.00K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 160.00K | 816.00K | 619.00K | 1.05M |
| CurrentProvisions | 117.00K | 208.00K | 258.00K | 103.00K |
| PayablesAndAccruedExpenses | 883.00K | 773.00K | 530.00K | 981.00K |
| Payables | 883.00K | 773.00K | 530.00K | 981.00K |
| AccountsPayable | 883.00K | 773.00K | 530.00K | 981.00K |
| TotalAssets | 8.75M | 9.90M | 17.18M | 26.83M |
| TotalNonCurrentAssets | 5.85M | 6.20M | 10.71M | 11.72M |
| NonCurrentPrepaidAssets | 1.00K | 2.00K | 52.00K | 569.00K |
| NonCurrentAccountsReceivable | 680.00K | 686.00K | 951.00K | 368.00K |
| InvestmentsAndAdvances | 0.00 | 12.00K | ||
| OtherInvestments | 0.00 | 12.00K | ||
| GoodwillAndOtherIntangibleAssets | 1.85M | 1.62M | 1.17M | 917.00K |
| OtherIntangibleAssets | 1.85M | 1.62M | 1.17M | 917.00K |
| NetPPE | 3.32M | 3.89M | 8.54M | 9.87M |
| AccumulatedDepreciation | -2.69M | -2.44M | -1.94M | -3.22M |
| GrossPPE | 6.01M | 6.33M | 10.47M | 13.09M |
| ConstructionInProgress | 0.00 | 0.00 | 108.00K | 50.00K |
| OtherProperties | 98.00K | 198.00K | 326.00K | 450.00K |
| MachineryFurnitureEquipment | 3.57M | 3.83M | 3.75M | 5.28M |
| BuildingsAndImprovements | 2.34M | 2.30M | 2.30M | 2.81M |
| LandAndImprovements | 0.00 | 4.10M | 4.44M | 4.61M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.90M | 3.71M | 6.47M | 15.11M |
| OtherCurrentAssets | 342.00K | 115.00K | 262.00K | 336.00K |
| AssetsHeldForSaleCurrent | 702.00K | 720.00K | 0.00 | |
| PrepaidAssets | 10.00K | 41.00K | 72.00K | 170.00K |
| Inventory | 1.36M | 1.54M | 2.65M | 3.55M |
| FinishedGoods | 256.00K | 441.00K | 533.00K | 717.00K |
| WorkInProcess | 0.00 | 18.00K | 584.00K | 2.20M |
| RawMaterials | 1.10M | 1.10M | 2.10M | 2.25M |
| Receivables | 77.00K | 91.00K | 131.00K | 597.00K |
| OtherReceivables | 43.00K | 52.00K | 24.00K | 472.00K |
| AccountsReceivable | 34.00K | 39.00K | 107.00K | 125.00K |
| AllowanceForDoubtfulAccountsReceivable | -12.00K | -24.00K | -17.00K | -93.00K |
| GrossAccountsReceivable | 46.00K | 63.00K | 124.00K | 218.00K |
| CashCashEquivalentsAndShortTermInvestments | 405.00K | 1.20M | 3.35M | 10.46M |
| OtherShortTermInvestments | 0.00 | 154.00K | 0.00 | 80.00K |
| CashAndCashEquivalents | 405.00K | 1.20M | 3.20M | 10.46M |
| CashEquivalents | 37.00K | 286.00K | 2.04M | |
| CashFinancial | 368.00K | 912.00K | 1.16M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -5.28M | -5.71M | -7.67M | -8.23M |
| RepaymentOfDebt | -3.00K | -3.00K | -3.00K | -3.00K |
| IssuanceOfDebt | 580.00K | |||
| IssuanceOfCapitalStock | 4.45M | 3.53M | 103.00K | 4.14M |
| CapitalExpenditure | -482.00K | -515.00K | -619.00K | -771.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 405.00K | 1.20M | 3.20M | 10.46M |
| BeginningCashPosition | 1.20M | 3.20M | 10.46M | 14.55M |
| EffectOfExchangeRateChanges | -7.00K | -6.00K | -82.00K | -26.00K |
| ChangesInCash | -786.00K | -1.99M | -7.18M | -4.06M |
| FinancingCashFlow | 4.45M | 3.52M | 100.00K | 4.14M |
| CashFlowFromContinuingFinancingActivities | 4.45M | 3.52M | 100.00K | 4.14M |
| NetCommonStockIssuance | 4.45M | 3.53M | 103.00K | 4.14M |
| CommonStockIssuance | 4.45M | 3.53M | 103.00K | 4.14M |
| NetIssuancePaymentsOfDebt | -3.00K | -3.00K | -3.00K | -3.00K |
| NetLongTermDebtIssuance | -3.00K | -3.00K | -3.00K | -3.00K |
| LongTermDebtPayments | -3.00K | -3.00K | -3.00K | -3.00K |
| LongTermDebtIssuance | 580.00K | |||
| InvestingCashFlow | -442.00K | -317.00K | -235.00K | -742.00K |
| CashFlowFromContinuingInvestingActivities | -442.00K | -317.00K | -235.00K | -742.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 154.00K | -154.00K | 0.00 |
| SaleOfInvestment | 0.00 | 5.13M | ||
| PurchaseOfInvestment | -154.00K | 0.00 | -149.00K | |
| NetIntangiblesPurchaseAndSale | -370.00K | -377.00K | -309.00K | -535.00K |
| PurchaseOfIntangibles | -370.00K | -377.00K | -309.00K | -535.00K |
| NetPPEPurchaseAndSale | -72.00K | -94.00K | 228.00K | -207.00K |
| SaleOfPPE | 40.00K | 44.00K | 538.00K | 29.00K |
| PurchaseOfPPE | -112.00K | -138.00K | -310.00K | -236.00K |
| OperatingCashFlow | -4.79M | -5.20M | -7.05M | -7.46M |
| CashFlowFromContinuingOperatingActivities | -4.79M | -5.20M | -7.05M | -7.46M |
| ChangeInWorkingCapital | -72.00K | 1.89M | 794.00K | 2.54M |
| ChangeInOtherWorkingCapital | 93.00K | |||
| ChangeInOtherCurrentLiabilities | -74.00K | -123.00K | -134.00K | -64.00K |
| ChangeInOtherCurrentAssets | 107.00K | 444.00K | -26.00K | -296.00K |
| ChangeInPayablesAndAccruedExpense | -90.00K | 440.00K | -539.00K | 375.00K |
| ChangeInAccruedExpense | -196.00K | 197.00K | -88.00K | -129.00K |
| ChangeInPayable | 106.00K | 243.00K | -451.00K | 504.00K |
| ChangeInAccountPayable | 106.00K | 243.00K | -451.00K | 504.00K |
| ChangeInPrepaidAssets | -187.00K | 150.00K | 591.00K | 541.00K |
| ChangeInInventory | 180.00K | 1.01M | 897.00K | 1.93M |
| ChangeInReceivables | -8.00K | -25.00K | 5.00K | 50.00K |
| ChangesInAccountReceivables | -8.00K | -25.00K | 5.00K | 50.00K |
| OtherNonCashItems | -430.00K | |||
| StockBasedCompensation | 1.64M | 1.77M | 2.84M | 2.20M |
| ProvisionandWriteOffofAssets | 13.00K | 93.00K | 126.00K | 1.72M |
| AssetImpairmentCharge | 152.00K | 3.45M | 0.00 | 882.00K |
| DepreciationAmortizationDepletion | 618.00K | 637.00K | 657.00K | 651.00K |
| DepreciationAndAmortization | 618.00K | 637.00K | 657.00K | 651.00K |
| AmortizationCashFlow | 74.00K | |||
| AmortizationOfIntangibles | 74.00K | |||
| Depreciation | 563.00K | |||
| OperatingGainsLosses | -25.00K | -44.00K | 39.00K | -430.00K |
| GainLossOnSaleOfPPE | -25.00K | -44.00K | 39.00K | 0.00 |
| NetIncomeFromContinuingOperations | -7.12M | -13.00M | -11.51M | -15.02M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IGC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|